Riess H - Search Results

1

Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine.

Vogel A, Kullmann F, Kunzmann V, Al-Batran SE, Oettle H, Plentz R, Siveke J, Springfeld C, Riess H. Vogel A, et al. Among authors: riess h. Oncol Res Treat. 2015;38(11):596-603. doi: 10.1159/000441310. Epub 2015 Oct 20. Oncol Res Treat. 2015. PMID: 26599274 Free article. Review.

2

Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer.

Oettle H, Riess H. Oettle H, et al. Among authors: riess h. Cancer. 2002 Aug 15;95(4 Suppl):912-22. doi: 10.1002/cncr.10758. Cancer. 2002. PMID: 12209671 Free article. Review.

3

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H. Oettle H, et al. Among authors: riess h. JAMA. 2013 Oct 9;310(14):1473-81. doi: 10.1001/jama.2013.279201. JAMA. 2013. PMID: 24104372 Clinical Trial.

4

Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma.

Oettle H, Arnold D, Esser M, Huhn D, Riess H. Oettle H, et al. Among authors: riess h. Anticancer Drugs. 2000 Sep;11(8):635-8. doi: 10.1097/00001813-200009000-00006. Anticancer Drugs. 2000. PMID: 11081455 Clinical Trial.

5

[Adjuvant therapy of pancreatic carcinoma].

Oettle H, Arnold D, Riess H. Oettle H, et al. Among authors: riess h. Praxis (Bern 1994). 2000 Nov 30;89(48):2017-25. Praxis (Bern 1994). 2000. PMID: 11142141 Review. German.

6

The role of gemcitabine alone and in combination in the treatment of pancreatic cancer.

Oettle H, Arnold D, Hempel C, Riess H. Oettle H, et al. Among authors: riess h. Anticancer Drugs. 2000 Nov;11(10):771-86. doi: 10.1097/00001813-200011000-00001. Anticancer Drugs. 2000. PMID: 11142685 Review.

7

Pancreatic cancer: step by step forward.

Riess H, Goerke A, Oettle H. Riess H, et al. Recent Results Cancer Res. 2008;177:1-2. doi: 10.1007/978-3-540-71279-4_1. Recent Results Cancer Res. 2008. PMID: 18084941 No abstract available.

8

Second-line therapy in refractory pancreatic cancer. results of a phase II study.

Pelzer U, Stieler J, Roll L, Hilbig A, Dörken B, Riess H, Oettle H. Pelzer U, et al. Among authors: riess h. Onkologie. 2009 Mar;32(3):99-102. doi: 10.1159/000197769. Epub 2009 Feb 18. Onkologie. 2009. PMID: 19295247 Clinical Trial.

9

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.

Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H, Oettle H. Pelzer U, et al. Among authors: riess h. Eur J Cancer. 2011 Jul;47(11):1676-81. doi: 10.1016/j.ejca.2011.04.011. Epub 2011 May 10. Eur J Cancer. 2011. PMID: 21565490 Clinical Trial.

10

Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study.

Sinn M, Striefler JK, Sinn BV, Sallmon D, Bischoff S, Stieler JM, Pelzer U, Bahra M, Neuhaus P, Dörken B, Denkert C, Riess H, Oettle H. Sinn M, et al. Among authors: riess h. J Surg Oncol. 2013 Nov;108(6):398-402. doi: 10.1002/jso.23409. Epub 2013 Aug 23. J Surg Oncol. 2013. PMID: 24038103 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

460 results

Search Page